Peptide therapy claims on TikTok: what the science actually supports

What's this video probably claiming?

Accounts in the @new.wave.longevity category tend to cluster around a familiar pitch: peptides like BPC-157, TB-500, CJC-1295, ipamorelin, and GHK-Cu are framed as next-generation tools for tissue repair, fat loss, anti-aging, and growth hormone optimization. The implicit argument is usually that these compounds do what pharmaceuticals do, but cleaner, smarter, and with fewer side effects. You'll often hear claims about synergistic "stacking" of peptides, accelerated recovery from injury, and growth hormone secretagogues like MK-677 or CJC-1295/ipamorelin combinations producing meaningful body composition changes. Semax and selank get positioned as nootropic and anxiolytic alternatives with minimal risk profiles. Whether or not this specific video makes all of those claims, the creator's content category makes clear that's the territory being mapped.

What does the science actually show?

The honest answer is: it depends heavily on which peptide you're asking about, and the human data is thin across the board. BPC-157 has shown pro-healing effects in rodent models, including tendon and gut repair, but as of 2024 there are no published randomized controlled trials in humans. TB-500's active fragment (Tβ4) showed some cardiac repair signals in a Phase II trial by RegeneRx Biopharmaceuticals, but the company discontinued development due to inconclusive results. CJC-1295 with DAC increased IGF-1 levels by roughly 200-300% in a small 2006 study by Jetté et al. in Growth Hormone and IGF Research, but sustained supraphysiologic IGF-1 carries its own risks. MK-677 (ibutamoren) does raise GH and IGF-1 measurably, but a 2008 Nass et al. study in the Annals of Internal Medicine found increased fasting glucose and insulin resistance in elderly subjects at 25 mg/day over 12 months. GHK-Cu shows in vitro collagen synthesis activity, but clinical translation remains weak.

Where does the social media noise diverge from clinical reality?

The biggest gap is the leap from animal pharmacology to human therapeutic outcomes. BPC-157 is pharmacologically interesting in rat models, but rats are not humans, and the compound has not cleared Phase I safety trials in people. That's not a minor caveat. Social media creators routinely treat rodent data as proof of human efficacy, which isn't how drug development works. The second gap is regulatory status. BPC-157 and TB-500 are not FDA-approved for any indication. In 2023, the FDA removed BPC-157 from the list of bulk substances that can be compounded, citing a lack of clinical evidence and safety data. Creators rarely mention this. MK-677 is also not a peptide technically, it's a small molecule GH secretagogue, and it's not approved for use outside clinical trials. Framing these substances as safe, accessible, and evidence-backed without those disclosures is where the content crosses from education into something closer to promotion.

What should you actually know?

If you're considering peptide therapy, the regulatory and safety picture matters more than the mechanism-of-action explanations you'll find on TikTok. Compounded peptides vary in purity and concentration. A 2018 analysis published in Drug Testing and Analysis by Eadie et al. found significant labeling inaccuracies in peptide products sold outside pharmaceutical channels. Some compounds in this category, particularly growth hormone secretagogues, are prohibited in sport under WADA rules regardless of how they're sourced. Semax and selank have a longer research history in Russian clinical literature, including some small trials for cognitive and anxiolytic effects, but that body of research has significant methodological limitations and hasn't been replicated in Western regulatory contexts. The bottom line: mechanistic plausibility and rodent data are not substitutes for human safety and efficacy evidence. Any provider offering these compounds should be discussing that gap directly with you, not around it.